BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25373121)

  • 1. Are selective serotonin reuptake inhibitors associated with hepatocellular carcinoma in patients with hepatitis C?
    Pocha C; Knott A; Rector TS; Dieperink E
    J Clin Psychiatry; 2014 Oct; 75(10):e1122-6. PubMed ID: 25373121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective serotonin reuptake inhibitors use and hepatocellular carcinoma in patients with alcohol use disorder.
    Chen VC; Lee MJ; Yang YH; Lu ML; Chiu WC; Dewey ME
    Drug Alcohol Depend; 2021 Feb; 219():108495. PubMed ID: 33429293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with one million participants.
    Bhagavathula AS; Woolf B; Rahmani J; Vidyasagar K; Tesfaye W
    Eur J Clin Pharmacol; 2022 Apr; 78(4):547-555. PubMed ID: 35039907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective serotonin reuptake inhibitors and the risk of hepatocellular carcinoma in hepatitis B virus-infected patients.
    Chang CM; Hsieh MS; Yang TC; Hsieh VC; Chiang JH; Huang HH; How CK; Hu SY; Yen DH
    Cancer Manag Res; 2017; 9():709-720. PubMed ID: 29238221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.
    Kanwal F; Hoang T; Kramer JR; Asch SM; Goetz MB; Zeringue A; Richardson P; El-Serag HB
    Gastroenterology; 2011 Apr; 140(4):1182-1188.e1. PubMed ID: 21184757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    Am J Gastroenterol; 2014 Sep; 109(9):1427-35. PubMed ID: 25070058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective serotonin reuptake inhibitor treatment and depression are associated with poststroke mortality.
    Ried LD; Jia H; Feng H; Cameon R; Wang X; Tueth M; Wu SS
    Ann Pharmacother; 2011 Jul; 45(7-8):888-97. PubMed ID: 21750310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
    J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVES.
    Chen JY; Ren Y; Yan P; Belina ME; Chung RT; Butt AA
    J Viral Hepat; 2018 Jul; 25(7):825-833. PubMed ID: 29478294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection.
    Kramer JR; Kowalkowski MA; Duan Z; Chiao EY
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):456-62. PubMed ID: 25559606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
    Davila JA; Henderson L; Kramer JR; Kanwal F; Richardson PA; Duan Z; El-Serag HB
    Ann Intern Med; 2011 Jan; 154(2):85-93. PubMed ID: 21242365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events.
    Lee YC; Lin CH; Lin MS; Lu Y; Chang CH; Lin JW
    J Clin Psychiatry; 2016 Jan; 77(1):e1-7. PubMed ID: 26845272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
    Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
    Busby J; Mills K; Zhang SD; Liberante FG; Cardwell CR
    Breast Cancer Res; 2018 Jan; 20(1):4. PubMed ID: 29351761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
    Hedenstierna M; Nangarhari A; Weiland O; Aleman S
    Clin Infect Dis; 2016 Sep; 63(6):723-9. PubMed ID: 27282709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Serotonin Reuptake Inhibitor Use and Hip Fracture Risk Among Patients on Hemodialysis.
    Vangala C; Niu J; Montez-Rath ME; Yan J; Navaneethan SD; Winkelmayer WC
    Am J Kidney Dis; 2020 Mar; 75(3):351-360. PubMed ID: 31606233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents.
    Sun JW; Hernández-Díaz S; Haneuse S; Bourgeois FT; Vine SM; Olfson M; Bateman BT; Huybrechts KF
    JAMA Psychiatry; 2021 Jan; 78(1):91-100. PubMed ID: 32876659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
    Sun J; Althoff KN; Jing Y; Horberg MA; Buchacz K; Gill MJ; Justice AC; Rabkin CS; Goedert JJ; Sigel K; Cachay E; Park L; Lim JK; Kim HN; Lo Re V; Moore R; Sterling T; Peters MG; Achenbach CJ; Silverberg M; Thorne JE; Mayor AM; Crane HM; Kitahata MM; Klein M; Kirk GD;
    JAMA Netw Open; 2021 Feb; 4(2):e2037512. PubMed ID: 33595662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.